MP0730 / Molecular Partners - LARVOL DELTA

Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70 (GlobeNewswire) - "MP0730 is the third program in the Company's pipeline of targeted alpha radiotherapeutics, and a first-in-human program is expected to start mid-2027...The data outline an attractive biodistribution profile of the CD70-targeting Radio-DARPin lead candidate in tumor-bearing mice, with strong and sustained tumor uptake relative to healthy tissues, including kidney, liver and blood."

New trial • Pipeline update • Preclinical • Clear Cell Renal Cell Carcinoma